VIRX — Viracta Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Viracta Therapeutics Announces Closure Of Naval-1 Clinical Trial And Exploration Of Strategic Alternatives
Brief: Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Viracta Therapeutics Reports Q3 2024 Financial Results And Provides Business Update
Brief: Viracta Therapeutics announces reprioritization of resources to enhance focus on Nana-Val development program
Viracta Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Advance Auto Parts, Molina Healthcare, Walmart
Viracta Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Viracta Therapeutics Q2 net income USD -9.8 million
Viracta Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Viracta Therapeutics Announces Reduction In Force Of About 23% Of Workforce
Brief: Viracta Therapeutics Appoints Michael Faerm As Chief Financial Officer
Viracta Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Viracta Therapeutics Announces Positive Topline Nana-Val Results From Stage 1 Of The Naval-1 Trial
Brief: Viracta Therapeutics Inc Received A Written Notice From Nasdaq Informing Co That It Has Regained Compliance With Nasdaq's Listing Rule
Brief: Viracta Therapeutics' Dan Chevallard Informed Co He Was Resigning From His Positions As CFO
Viracta Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Viracta Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Viracta Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update